Navigation Links
Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential

NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2007 - AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today positive preliminary results from an investigational double-blind, placebo-controlled Phase 1/2 dose-escalating clinical trial of its typhoid fever vaccine candidate, Ty800, in healthy volunteers. The researchers found the single-dose, oral vaccine to be well tolerated and immunogenic, with over 90% of vaccinated subjects generating immune responses. Based on these excellent results, AVANT plans to further develop Ty800 to compete in the expanding typhoid fever vaccine market, which currently has over $200 million in annual sales. AVANT plans to initiate its own sponsored Phase 2 dose-ranging trial of Ty800 in mid-2007.

"Typhoid fever remains endemic in many developing areas of the world, as well as being an important potential health threat for travelers and military personnel in areas affected by the disease," said Dr. Mitchell B. Cohen, Principal Investigator in the study and Director of Gastroenterology, Hepatology and Nutrition at Cincinnati Children's Hospital Medical Center. "The development of an effective and practical vaccine for all ages will provide an important tool for controlling this disease. A safe typhoid fever vaccine that can be easily administered could significantly reduce the morbidity and mortality associated with typhoid fever."

"We are delighted with these results for our single-dose, oral Ty800 vaccine candidate," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "These results indicate that AVANT's vaccine may have significant potential advantages over the currently licensed vaccines, which offer limited protection rates of 50-80% and require either a single needle injection or three to four oral doses over the course of a week. We believe a more efficacious, easier-to-use typhoid fever vaccine could greatly expand the cur
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
2. SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
11. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
Post Your Comments:
(Date:8/29/2014)... 29, 2014 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... Morgan Stanley Global Healthcare Conference on Wednesday, September 10. ... Chief Executive Officer, will provide an update on the ... a.m., Pacific Daylight Time).   A webcast ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
(Date:8/30/2014)... August 30, 2014 In today’s world, ... increasingly difficult to get. Snoring and sleep apnea (a ... breathing stops) robs people and their bed partners of ... Up to 45% of the population snores and 20 ... apnea. Of these, only 10% have been diagnosed and ...
(Date:8/30/2014)... 2014 August 28th, 2014: With ... our society and the toll that takes on the ... that continuing education for physical therapists addresses this problem. ... therapists help others, Hands-On Seminars is offering discounts on ... Three learning styles are available to fit the individual ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 McLeod's ... full service auto repair shop with strong ties to the ... Family is happy to announce they have been chosen by ... one pick for auto repair. , Tim McLeod’s father, ... Auto Service sixty years ago. Although his son, Tim runs ...
(Date:8/30/2014)... 2014 The SI Joint Evaluation and ... six muscle energy techniques. Michael P. Reiman PT, DPT, ... examination techniques for the SI Joint. This ... live course presentation with North American Seminars. ... Applying a differential diagnosis approach to a thorough examination ...
(Date:8/30/2014)... 30, 2014 What challenges exist in ... the latest trends, concerns, and considerations? Sports Conflict ... Pendleton recently spoke with Woody Wommack, Southeast Football Recruiting ... issues in football recruiting. Notably, Wommack spoke on ... changes that he thinks are coming as a result ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... Response Systems,announced today two new contract awards, worth ... surge capacity for hospitals and,public health systems in ... Suffolk County, NY., The first contract, for ... the Idaho Central District Health Department. This,contract includes ...
... of connecting with doctors in real time, speeding care, study ... patients report to doctors on their symptoms and side effects ... Even the sickest cancer patients are willing and capable of ... Cancer Center in New York City. , "Cancer care has ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading ... announced that it has entered into a definitive ... cash transaction valued at,approximately $26 million, subject to ... that brings quality healthcare to the,bedside through a ...
... rate of decline in lung function in children and adolescents ... Researchers found that patients with cystic fibrosis (CF) who took ... loss of lung function compared to those who did not ... two to seven years. , It is fairly evident ...
... Assay Developed Specifically for Resource-Limited ... Settings Joins Global Procurement Consortium, UPPSALA, Sweden, November ... today announced an agreement with the Clinton,Foundation HIV/AIDS Initiative ... immediately available to members of CHAI,s,Procurement Consortium at a ...
... Nov. 29 AstraZeneca (NYSE:,AZN) today announced that the ... an additional six-month period of,exclusivity to market ARIMIDEX(R) (anastrozole) ... to pediatric exclusivity being,granted by the FDA, the patent ... is currently approved in the US for the for ...
Cached Medicine News:Health News:BLU-MED Announces New Medical Preparedness Contracts 2Health News:Cancer Patients Gain From Reporting Symptoms Online 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 3Health News:Ibuprofen associated with slower lung function decline in children with cystic fibrosis 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 2Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 3
... Laserex Super Q is an Nd: YAG ... and reliable means for performing posterior capsulotomy, ... Q delivers benchmark performance in an elegant, ... Laserex Super Q produces a 1064 nm ...
... Ultrasonix ES500 system is an innovative, ... that provides excellent clinical performance. The ... processing of the ES500 system deliver ... and every system offers a full ...
Protects the eye during or after surgery or trauma. Smooth edges need no protective cover. Connected with elastic at nose. Adjustable hook/loop material for a comfortable fit....
Protects the eye during or after surgery or trauma...
Medicine Products: